"Ranbaxy strongly denies allegations contained in the motion that has been filed (not granted) by the US Department of Justice seeking certain documents," the company said in a statement.
The company said the US Food and Drugs Administrator (USFDA) has gathered over 200 random samples of various products marketed by it the US.
These products have been independently tested by the USFDA and were found to be complying with all the specifications, it added.
"Under these circumstances the company finds that the allegations are baseless."
More From This Section
A response would be filed today in US court to defend the company against the motion filed by US Department of Justice, it said.
The company's business in the US continues as normal and it also clarifies that the company's deal with Daiichi Sankyo is binding and final and remains on track, it added.
Meanwhile Daiichi Daiichi Sankyo officials asserted the deal with Ranbaxy for acquiring majority stake in Gurgaon -based company remained intact.
"We are aware of the fact that US FDA has filed a motion against Ranbaxy and the development would not affect the deal with the company for acquiring majority stake in the company," Daiichi Sankyo spokerperson said while refusing to comment further on the issue.
Earlier, US Department of Justice has made number of allegations against the company while filing a motion against the company.